PVLA NASDAQ
Palvella Therapeutics, Inc.
1W: -4.1%
1M: -13.4%
3M: -5.6%
YTD: +32.1%
1Y: +109.5%
$132.47
-0.26 (-0.20%)
Weekly Expected Move ±5.3%
$119
$126
$132
$139
$146
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships7
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-03-25
Earliest Filing
2023-12-01
Latest Filing
investor: 5
partner: 2
Counterparties (Filed by PVLA)
7 relationshipsCompanies named in PVLA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Biotechnology Value Fund, L.P. | BTMD | investor | Exchanged 5,000,000 shares of common stock for 5,000 shares of Series E Convertible Preferred Stock | 2021-05-21 | View |
| Biotechnology Value Fund II, L.P. | BTMD | investor | Exchanged 5,000,000 shares of common stock for 5,000 shares of Series E Convertible Preferred Stock | 2021-05-21 | View |
| Biotechnology Value Trading Fund OS, L.P. | BTMD | investor | Exchanged 5,000,000 shares of common stock for 5,000 shares of Series E Convertible Preferred Stock | 2021-05-21 | View |
| MSI BVF SPV, L.L.C. | — | investor | Signatory to the Exchange Agreement regarding the preferred stock exchange | 2021-05-21 | View |
| Boston Pharmaceuticals | — | partner | Exclusive licensee of PRS-342 under an agreement with Pieris Pharmaceuticals, Inc. | 2021-04-26 | View |
| Boston Pharma Holdings, LLC | — | partner | Parent company of Boston Pharmaceuticals, Inc. | 2021-04-26 | View |
| Seagen Inc. | SGEN | investor | Strategic equity investment and collaboration for combination study of cinrebafusp alfa and TUKYSA | 2021-03-25 | View |
Mentioned As Counterparty
1 mentionsOther companies that named PVLA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-14 | Other Events; Exhibits | View | |
| 2026-06-30 | Officer/Director Change | View | |
| 2026-06-16 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-20 | Other Events; Exhibits | View | |
| 2026-05-15 | Other Events; Exhibits | View | |
| 2026-05-13 | Other Events | View | |
| 2026-05-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-13 | Officer/Director Change | View | |
| 2026-04-07 | Other Events; Exhibits | View | |
| 2026-03-31 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-02-26 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-24 | Results of Operations and Financial Condition | View | |
| 2026-02-24 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-24 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-29 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-15 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR